Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: Comparison of high loading dose (600 mg) versus low loading dose (300 mg)

Coronary Artery Disease

Volumn 20, Issue 2, 2009, Pages 150-154

  Jung, Jae Hun ^a   Min, Pil Ki ^b   Lee, Sang Hak ^c   Sung, Chong Won ^a   Choi, Seonghoon ^a   Cho, Jung Rae ^a   Lee, Namho ^a   Byun, Ki Hyun ^d  

^a Hallym University Medical Center   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Kwandong University College of Medicine   (South Korea)

Author keywords

Clopidogrel; Myocardial infarction; Percutaneous transluminal coronary angioplasty

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY STENT; DEATH; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG MEGADOSE; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION; STROKE; SURGICAL TECHNIQUE; THROMBOCYTE AGGREGATION INHIBITION; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION; INSTRUMENTATION; MIDDLE AGED; MORTALITY; STENT; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; STENTS; STROKE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 66349137730     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3283262de2     Document Type: Article

References (25)

1. Moshfegh K, Redondo M, Julmy F, Wuillemin WA, Gebauer MU, Haeberli A, et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 2000; 36:699-705.
2. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Clopidogrel in Unstable angina to prevent Recurrent Events Trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358:527-533.
3. Neumann FJ, Kastrati A, Pogatsa-Murray G, Mehilli J, Bollwein H, Bestehorn HP, et al. Evaluation of prolonged antithrombotic pretreatment (cooling-off strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA 2003; 290:1593- 1599.
4. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study. Circulation 2005; 111:2099-2106.
5. Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 2001; 38:2114-2130.
6. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.
7. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366:1607-1621.
8. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352:1179-1189.
9. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY Study. JAMA 2005; 294:1224-1232.
10. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100:1667-1672.
11. Thebault JJ, Kieffer G, Cariou R. Single-dose pharmacodynamics of clopidogrel. Semin Thromb Hemost 1999; 25 (Suppl 2):3-8.
12. Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000; 101:2823-2828.
13. Chan AW, Moliterno DJ, Berger PB, Stone GW, DiBattiste PM, Yakubov SL, et al. TARGET investigators. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol 2003; 42:1188-1195.
14. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, et al. CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411-2420.
15. Müller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa-Murray G, Schomig A, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85:92-93.
16. Leimbach ME, Peyrou V, Marzec UM, Chronos NA, King SB III, Harker LA. Single-dose clopidogrel inhibition of platelet adenosine receptor function in patients with atherosclerotic coronary artery disease. Circulation 1999; 100 (Suppl 1):I681.
17. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005; 111:2560-2564.
18. Kastrati A, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM, et al. Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350:232-238.
19. Kandzari DE, Berger PB, Kastrati A, Steinhubl SR, Mehilli J, Dotzer F, et al. ISAR-REACT Study investigators. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004; 44:2133-2136.
20. Wolfram RM, Torguson RL, Hassani SE, Xue Z, Gevorkian N, Pichard AD, et al. Clopidogrel loading dose (300 vs. 600 mg) strategies for patients with stable angina pectoris subjected to percutaneous coronary intervention. Am J Cardiol 2006; 97:984-989.
21. Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Carvajal J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006; 48:1339-1345.
22. King SB III, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008; 51:172-209.
23. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008; 29:2909-2945.
24. Von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005; 112:2946-2950.
25. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, et al. ALBION Trial investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) Trial. J Am Coll Cardiol 2006; 48:931-938.